OncoCyte Q1 2024 GAAP EPS $(1.13) Misses $(0.67) Estimate, Sales $176.000K Miss $350.000K Estimate
OncoCyte Q1 2024 GAAP EPS $(1.13) Misses $(0.67) Estimate, Sales $176.000K Miss $350.000K Estimate
OncoCyte 2024 年第一季度公認會計准則每股收益 (1.13) 未達到預期 (0.67) 美元，銷售額爲 176.000 美元，未達預期 350.000 美元
OncoCyte (NASDAQ:OCX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.67) by 68.66 percent. This is a 237.8 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $176.000 thousand which missed the analyst consensus estimate of $350.000 thousand by 49.71 percent. This is a 40.74 percent decrease over sales of $297.000 thousand the same period last year.
OncoCyte（納斯達克股票代碼：OCX）公佈的季度虧損爲每股1.13美元，比分析師普遍預期的0.67美元（0.67美元）低68.66％。與去年同期的每股收益0.82美元相比，下降了237.8％。該公司公佈的季度銷售額爲17.6萬美元，比分析師普遍預期的35萬美元低49.71％。這比去年同期的29.7萬美元的銷售額下降了40.74％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。